Immune Response to HPV Vaccine Among HIV-1-infected Subjects in Brazil
- Conditions
- Infection
- Interventions
- Biological: HPV vaccine
- Registration Number
- NCT02236234
- Lead Sponsor
- University of Sao Paulo
- Brief Summary
Besides the specific response to vaccine antigens, the investigators will analyze the anti-HPV immune response in HIV-1-infected men in different strata of immune deficiency. The hypothesis will be tested by stratification by T CD4 + lymphocytes in an attempt to assess the range of the count with the highest possibility of vaccine response. Thus, knowledge of vaccine response in HIV-infected patients, indicate which patients would have greater potential for vaccine response in vivo.
- Detailed Description
The study will be divided into three groups. Patients with HIV-1 infection will be subdivided into groups according to T CD4 + lymphocytes at the time of vaccination: Over 500 CD4 T cells count and bellow 500 CD4 T cells count. A healthy control group will be also studied.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 30
HIV
- Men with age between 35 and 45 years of age.
- Current or previous infection with human papillomavirus (HPV)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Vaccine HPV vaccine one group with HPV vaccine
- Primary Outcome Measures
Name Time Method Presence of Anti-HPV antibody titers 0, 30 and 180 days of vaccination anti-HPV The anti-HPV titers will be compared from baseline to the date of sample collection
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Institute of Tropical Medicine of Sao Paulo
🇧🇷Sao Paulo, SP, Brazil